Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: A pilot study

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 1217-1222

  Cabrera, Carlos ^a   Casanova, Ciro ^b   Martín, Yolanda ^c   Mirabal, Virginia ^c   Sánchez, María del Carmen ^d   Álvarez, Felisa ^e   Juliá, Gabriel ^a   Cabrera Navarro, Pedro ^a   García Bello, Miguel Ángel ^a   Marín, José María ^f   de Torres, Juan Pablo ^g   Divo, Miguel ^h   Celli, Bartolomé ^h  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^c Arucas Health Center   (Spain)

^d Primary Care Las Palmas de Gran Canaria   (Spain)

^e La Feria Health Center   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Algorithm; COPD; Primary care; Treatment

Indexed keywords

CORTICOSTEROID; BRONCHODILATING AGENT;

AGED; ALGORITHM; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROSS-SECTIONAL STUDY; DYSPNEA; DYSPNEA BASED TREATMENT ALGORITHM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PILOT STUDY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RATING SCALE; RESPIRATORY CARE; SCORING SYSTEM; SPAIN; VALIDITY; CLASSIFICATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; DISEASE COURSE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PRIMARY HEALTH CARE; PROTOCOL COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY;

ADMINISTRATION, INHALATION; AGED; ALGORITHMS; BRONCHODILATOR AGENTS; CLINICAL DECISION-MAKING; CROSS-SECTIONAL STUDIES; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GUIDELINE ADHERENCE; HUMANS; LUNG; MALE; MIDDLE AGED; PATIENT SELECTION; PILOT PROJECTS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84973472626     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S100853     Document Type: Article

References (29)

1. European Respiratory Society. European Lung White Book. Huddersfield: European Respiratory Society Journals, Ltd; 2003.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
3. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet. 2007; 370: 741-750.
4. Cabrera Lopez C, Julia Serda G, Cabrera Lacalzada C, et al. Prevalence of chronic obstructive pulmonary disease in the Canary Islands. Arch Bronconeumol. 2014; 50: 272-277.
5. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009; 64: 863-868.
6. The Global Strategy for the Diagnosis MAPOCOPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Available from: http: //www. goldcopd. org/. Accessed April 14, 2016.
7. Chavez PC, Shokar NK. Diagnosis and management of chronic obstructive pulmonary disease (COPD) in a primary care clinic. COPD. 2009; 6: 446-451.
8. Perez X, Wisnivesky JP, Lurslurchachai L, et al. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012; 106: 374-381.
9. Bourbeau J, Sebaldt RJ, Day A, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J. 2008; 15: 13-19.
10. Lange P, Rasmussen FV, Borgeskov H, et al. The quality of COPD care in general practice in Denmark: the KVASIMODO study. Prim Care Respir J. 2007; 16: 174-181.
11. Li F, Cai Y, Zhu Y, et al. The evaluation of general practitioners' awareness/knowledge and adherence to the GOLD guidelines in a Shanghai Suburb. Asia Pac J Public Health. 2015; 27(2): NP2067-NP2078.
12. Rutschmann OT, Janssens J-P, Vermeulen B, et al. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med. 2004; 98: 932-937.
13. Miravitlles M, Sicras A, Crespo C, et al. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting. Ther Adv Respir Dis. 2013; 7: 139-150.
14. Agusti A, Fabbri LM. Inhaled steroids in COPD: when should they be used? Lancet Respir Med. 2014; 2: 869-871.
15. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. Can Respir J. 2008; 15: 1A.
16. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23: 932.
17. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54: 581-586.
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005; 26: 319-338.
19. Castellsagué J, Burgos F, Sunyer J, et al. Prediction equations for forced spirometry from European origin populations. Barcelona Collaborative Group on Reference Values for Pulmonary Function Testing and the Spanish Group of the European Community Respiratory Health Survey. Respir Med. 1998; 92: 401-407.
20. Bilder CR, Zhang B, Schaarschmidt F, et al. binGroup: a package for group testing. R J. 2010; 2: 56-60.
21. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434-1440.
22. Almagro P, Martinez-Camblor P, Soriano JB, et al. Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One. 2014; 9: e89866.
23. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005.
24. Casanova C, Aguirre-Jaime A, de Torres JP, et al. Longitudinal assessment in COPD patients: multidimensional variability and outcomes. Eur Respir J. 2014; 43: 745-753.
25. Casanova C, de Torres JP, Aguirre-Jaime A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011; 184: 1015-1021.
26. Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015; 373: 111-122.
27. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest. 2001; 119: 1347-1356.
28. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005; 26: 214-222.
29. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012; 186: 975-981.